全文获取类型
收费全文 | 1324篇 |
免费 | 84篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 59篇 |
妇产科学 | 14篇 |
基础医学 | 151篇 |
口腔科学 | 30篇 |
临床医学 | 248篇 |
内科学 | 320篇 |
皮肤病学 | 16篇 |
神经病学 | 27篇 |
特种医学 | 242篇 |
外科学 | 86篇 |
综合类 | 31篇 |
预防医学 | 52篇 |
眼科学 | 8篇 |
药学 | 93篇 |
中国医学 | 5篇 |
肿瘤学 | 31篇 |
出版年
2024年 | 2篇 |
2023年 | 8篇 |
2022年 | 2篇 |
2021年 | 9篇 |
2020年 | 6篇 |
2019年 | 7篇 |
2018年 | 26篇 |
2017年 | 15篇 |
2016年 | 20篇 |
2015年 | 25篇 |
2014年 | 30篇 |
2013年 | 33篇 |
2012年 | 43篇 |
2011年 | 41篇 |
2010年 | 55篇 |
2009年 | 94篇 |
2008年 | 102篇 |
2007年 | 99篇 |
2006年 | 77篇 |
2005年 | 42篇 |
2004年 | 11篇 |
2003年 | 14篇 |
2002年 | 10篇 |
2001年 | 15篇 |
2000年 | 12篇 |
1999年 | 14篇 |
1998年 | 49篇 |
1997年 | 54篇 |
1996年 | 66篇 |
1995年 | 48篇 |
1994年 | 43篇 |
1993年 | 47篇 |
1992年 | 14篇 |
1991年 | 7篇 |
1990年 | 14篇 |
1989年 | 34篇 |
1988年 | 30篇 |
1987年 | 32篇 |
1986年 | 33篇 |
1985年 | 23篇 |
1984年 | 15篇 |
1983年 | 9篇 |
1982年 | 22篇 |
1981年 | 14篇 |
1980年 | 8篇 |
1979年 | 2篇 |
1978年 | 4篇 |
1977年 | 12篇 |
1976年 | 11篇 |
1975年 | 13篇 |
排序方式: 共有1417条查询结果,搜索用时 46 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
M. E. Falagas S. K. Kasiakou D. P. Kofteridis G. Roditakis G. Samonis 《European journal of clinical microbiology & infectious diseases》2006,25(9):596-599
The prospective case series study presented here was conducted to assess the outcome of patients with infections caused by polymyxin-only-susceptible (POS) gram-negative bacteria managed with intravenous colistin. Between July 2003 and April 2005 a total of 27 patients were infected with a POS gram-negative bacterium and received intravenous colistin at a dose of 2 million international units (MIU) (160 mg or 66.7 mg colistin base) every 8 h for a mean (±SD) duration of 13.9 (±7.5) days. Nine patients had ventilator-associated pneumonia and received, in addition to the intravenous colistin therapy, 1 MIU (80 mg or 33.3 mg colistin base) aerosolized colistin every 12 h for a mean (±SD) duration of 13 (±6.5) days. The predominant pathogens were Pseudomonas aeruginosa (n=17) and Acinetobacter baumannii (n=12); in two patients both pathogens were isolated from one clinical specimen. In-hospital mortality and clinical response were 15% and 85%, respectively. Colistin-associated nephrotoxicity was observed in two of the 27 patients. POS gram-negative pathogens represent a major threat for hospitalized patients. Colistin appears to be an effective and safe treatment, even in patients with severe underlying diseases. 相似文献
3.
Research brief: A bibliometric analysis by geographic area of published research in several biomedical fields, 1995–2003 下载免费PDF全文
Matthew E. Falagas Argyris S. Michalopoulos Ioannis A. Bliziotis Elpidoforos S. Soteriades 《Canadian Medical Association journal》2006,175(11):1389-1390
We summarized the findings of several studies of ours to compare the quantity and quality of published research from around the world for the years 1995 to 2003. We evaluated the number of articles published and their mean journal impact factor. We also studied the research productivity of various areas adjusted for gross domestic product (GDP) and population. We found that Western Europe leads the world in published research on infectious diseases–microbiology (82 342 articles [38.8%]) and in cardiopulmonary medicine (67 783 articles [39.5%]), whereas the United States ranks first in the fields of preventive medicine, public health and epidemiology both in quantity (23 918 articles [49.1%]) and quality of published papers. However, after adjustments for GDP, Canada ranked first, with the United States and Oceania following closely behind. All of the developing regions had only small research contributions in all of the biomedical fields examined. 相似文献
4.
5.
6.
7.
8.
9.
10.